module.exports = [
    {
        articleID: "901602",
        componentNumber: null, 
        slidePath: "901/602",
        rawSlides: `&lt;&lt;insert slide 1&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;</strong> <strong>Cancer-Associated Thrombosis: Emerging Concepts and Paradigms</strong></p>
        &lt;&lt;insert slide 2&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;</strong> Panelists</p>
        &lt;&lt;insert slide 3&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; Cancer-Associated Thrombosis: Who Is at Risk?</strong></p>
        
        &#8226;	Separating cancer into subcategories of patients who can or are likely to get blood clots vs those who are not likely to get blood clots is key
        
        &#8226;	A single risk factor does not predict the full assessment of risk in this population 
        <p></p>
        
        &lt;&lt;insert slide 4&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;Cancer-Associated Thrombosis: <em>How to Identify Those at Risk <sup>[1]</sup></em></strong></p>
        
        &#8226;	Surveys suggest that cancer patients are very unware of the risk of venous thromboembolism (VTE)
        
        &#8226;	They are very aware of becoming nauseated, having emesis, and getting infections and when to report these problems
        
        &#8226;	They are not aware of leg swelling or increased shortness of breath or sudden onset of chest pain as being concerning
        
        &#8226;	Providers must assess the risk, have a discussion, and educate patients about warning signs and symptoms of VTE 
        &lt;&lt;insert slide 5&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;</strong> <strong>Risk of VTE in Medical Patients<sup>[2]</sup></strong></p>
        &lt;&lt;insert slide 6&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;Primary Prevention Trials<sup>[3,4]</sup></strong></p>
        
        &#8226;	Two studies that will be completed soon are looking at prophylaxis with either rivaroxaban 10 mg once a day vs placebo or apixaban 2.5 mg twice a day vs placebo
        
        &#8226;	Both studies identify the highest risk patients 
        &lt;&lt;insert slide 7&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;Bleeding Risk in Patients With Cancer</strong></p>
        &lt;&lt;insert slide 8&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;Treating the Patient With VTE<sup>[1]</sup></strong></p>
        &lt;&lt;insert slide 9&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;How Long to Treat?<sup>[1]</sup></strong></p>
        <p></p>
        
        &lt;&lt;insert slide 10&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; NOACs vs LMWH In Patients With Cancer<sup>[5,6]</sup></strong></p>
        &lt;&lt;insert slide 11&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; Study Results<sup>[5,6]</sup></strong></p>
        
        &#8226;	In both those trials, the non-vitamin K antagonist oral anticoagulants (NOACs) were better in terms of reducing the risk of recurrent VTE with some increase in bleeding
        
        &#8226;	Both trials assessed the 6-month time point
        
        <tt>o	</tt>The Hokusai study extended to 12 months, but for most patients the median time was around 6 months 
        <p></p>
        
        &lt;&lt;insert slide 12&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;LMWH and VKAs<sup>[7]</sup></strong></p>
        
        &#8226;	The advantage of low-molecular heparin vs vitamin K antagonist (VKA) is that you can titrate the dose 
        
        &#8226;	If, for example, a patient presents with gastrointestinal bleeding (GI), a lower dose can be used to start and then the dose can be gradually increased when bleeding ceases
        
        &#8226;	Or, if a patient develops thrombocytopenia, you can titrate the dose down and ramp it back up again as the platelet count recovers
        
        &#8226;	There is a flexibility in dosing, which is not seen with VKAs
        
        <tt>o	</tt>VKAs are only effective when the international normalized ratio (INR) is between 2 and 3, and that is difficult to maintain 
        &lt;&lt;insert slide 13&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;Study Results (cont)<sup>[5,6]</sup></strong></p>
        
        &#8226;	Hokusai VTE Cancer and SELECT-D studies had similar results
        
        &#8226;	Bleeding was seen especially in patients with GI cancer 
        
        &#8226;	There are now broader options for anticoagulation to manage thrombosis in our cancer patients 
        &lt;&lt;insert slide 14&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; Patient Persistence with Anticoagulant: <em>LMWH vs Oral Agents<sup>[8]</sup></em></strong></p>
        
        &#8226;	Consistently in studies looking at different populations -- older patients, younger patients, patients with private insurance, patients with Medicare -- the results are the same
        
        <tt>o	</tt>Persistence on low molecular weight heparin (LMWH) is much lower than persistence on any oral agent, including VKAs
        
        &#8226;	There is clearly a limitation of prolonged parenteral therapy that needs to be borne in mind
        
        <p> </p>
        &lt;&lt;insert slide 15&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; Challenges of Anticoagulation Therapy</strong></p>
        
        &#8226;	In the Hokusai VTE Cancer study, for example, only about 11% of the patients had hematological malignancies; thrombocytopenia was not a big issue
        
        &#8226;	In patents with lymphoma or leukemia, thrombocytopenia becomes a major challenge 
        
        &#8226;	If anticoagulants are stopped, the risk of reoccurrence is at least around 20% in that first year<sup>[9]</sup>
        &lt;&lt;insert slide 16&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; Ottawa Risk Score<sup>[10]</sup></strong></p>
        
        &#8226;	The Ottawa score has not been validated in every study
        
        &#8226;	It is very good at predicting low-risk patients, but not so good at predicting high-risk patients 
        
        &#8226;	The other challenge is all of these risk assessment tools were developed in the LMWH era
        
        <p> </p>
        
        &lt;&lt;insert slide 17&gt;&gt;
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Tailoring Treatment</strong></p>
        &lt;&lt;insert slide 18&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; ISTH Guidance Statement<sup>[11]</sup></strong></p>
        
        &#8226;	The term <em>suggest</em> has a specific meaning in the guidelines
        
        &#8226;	The Hokusai VTE Cancer study carefully captured the different chemotherapeutic or biological agents being used by patients
        
        <tt>o	</tt>A wide array of different agents was used, and there did not seem to be a problem with them 
        &lt;&lt;insert slide 19&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;CARAVAGGIO<sup>[12]</sup></strong></p>
        &lt;&lt;insert slide 20&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; Managing Anticoagulation</strong></p>
        
        &#8226;	New International Society on Thrombosis and Haemostasis (ISTH) guidelines recommend taking patient preferences and values into account and having an informed discussion about the risk of bleeding and risk of recurrent VTE
        <p></p>
        
        &lt;&lt;insert slide 21&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt; Managing Anticoagulation (cont)</strong></p>
        
        &lt;&lt;insert slide 22&gt;&gt;
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Summary </strong></p>
        &lt;&lt;insert slide 23&gt;&gt;
        <p><strong>&lt;&lt;level 2&gt;&gt;Thank you</strong></p>
        
        <p> <em>This content has been condensed for improved clarity.</em></p>
        
        
        <table border="1" cellpadding="3" cellspacing="1">
        <tr valign="top">
        `
    }
];